Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2007, p. 3804-3816, Vol. 27, No. 10
0270-7306/07/$08.00+0 doi:10.1128/MCB.01590-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
,
Angélica Figueroa,
Catherine Hogan,
Emma C. Ferber,
Carl Uli Bialucha,
Joanna Adams,
Emily C. N. Richardson, and
Yasuyuki Fujita*
MRC Laboratory for Molecular Cell Biology and Cell Biology Unit and Department of Biology, University College London, Gower Street, London WC1E 6BT, United Kingdom
Received 25 August 2006/ Returned for modification 3 October 2006/ Accepted 26 February 2007
|
|
|---|
|
|
|---|
-catenin, respectively. ß-Catenin binds to
-catenin, which in turn associates with actin filaments. While the extracellular domain of cadherin induces cell-cell adhesion in the presence of Ca2+, an interaction between the cytoplasmic domain of cadherin and the underlying actin cytoskeleton is also required for the construction of tight and compact cell-cell adhesions (for a review, see reference 32). Cadherin-based cell-cell contacts are not static but are often dynamically modulated during various physiological and pathological processes including mitosis, oncogenesis, and epithelial-mesenchymal transition during embryonic development. In all these processes, cadherin has been reported to be down-regulated by endocytosis (1, 19, 29, 39). However, the molecular mechanisms for the induction of endocytosis are not clearly understood. In cell culture systems, two experimental stimuli enhance the endocytosis of E-cadherin: the activation of tyrosine kinases and low-Ca2+ treatment. Upon the activation of tyrosine kinases such as Src, hepatocyte growth factor and epidermal growth factor receptors, E-cadherin and its binding proteins become tyrosine phosphorylated, which induces the recruitment of the E3-ubiquitin ligase Hakai and the ubiquitination of the E-cadherin complex. The complex is then internalized and sorted into lysosomes for protein degradation (11, 31). In contrast, low-Ca2+ treatment triggers the internalization of E-cadherin that occurs independently of tyrosine phosphorylation and ubiquitination, and the internalized E-cadherin is recycled back to the plasma membrane (8, 21, 31). The molecular mechanism for this process largely remains to be clarified.
Casein kinase 1 (CK1) is a serine/threonine kinase that is evolutionarily conserved from yeast to mammals (for a review, see reference 20). In mammals, at least seven CK1 isoforms (
, ß,
1,
2,
3,
, and
) and their splice variants have been identified, which are all ubiquitously expressed. All CK1 isoforms are highly homologous within their kinase domains, but they differ in the lengths and primary structures of their noncatalytic domains. CK1 phosphorylates many substrates that are involved in various cellular processes including cell differentiation, proliferation, membrane transport, and oncogenesis. For example, in Saccharomyces cerevisiae, CK1 phosphorylates and enhances the endocytosis of many membrane proteins including the
-factor pheromone receptor and uracil permease (16, 24, 25). In both invertebrates and vertebrates, several CK1 isoforms have been reported to have a regulatory role in the wingless (Wnt) signaling pathway (10, 12, 23, 40, 41). In the present study, we report that the cytoplasmic domain of cadherin is a novel substrate for CK1 and that the subsequent phosphorylation of E-cadherin negatively regulates cadherin-based cell-cell adhesions.
|
|
|---|
-catenin, -ß-catenin, -CK1
, and -EEA1 antibodies were from Transduction Laboratories. Chicken anti-CK1
antibody from EnCor Biotechnology (Alachua, FL) was used for Western blotting, and goat anti-CK1
antibody from Santa Cruz (Santa Cruz, CA) was used for immunofluorescence. Mouse anti-Myc (4A6) antibody was obtained from Upstate (Charlottesville, VA), and rabbit anti-Myc (A14) antibody was from Santa Cruz. All antibodies were used at dilutions of 1:1,000 for Western blotting and 1:100 for immunofluorescence, except for anti-CK1
antibody, which was used at a dilution of 1:5,000 for Western blotting.
To construct pCAN-Myc-CK1
(full length) and pCAN-Myc-CK1
(full-length), the cDNAs of rat CK1
and Xenopus laevis CK1
were amplified from pCS2-CK1
and pCS2-CK1
by PCR using the primers 5'-CGAATTCGGATCCGCATGGCGAGCAGCAGCGGCTCC-3' and 5'-GGAATTCGCGGCCGCTTAGAAACCTGTGGGGGTTTGGGCC-3' and 5'-CATCGATGTCGACACATGGAGCTGAGAGTGGGGAAC-3' and 5'-CATCGATATCGATACATGGAGCTGAGAGTGGGGAAC-3', respectively. pCS2-CK1
and pCS2-CK1
were kindly provided by X. He (Harvard Medical School, Boston, MA). The amplified cDNAs of CK1
and CK1
were cloned into BamHI/NotI and ClaI/NotI sites of the pCAN-Myc vector, respectively. To construct pcDNA4/TO/GFP-CK1
, the cDNA of rat CK1
was excised from pCAN-Myc-CK1
(BamHI/NotI) and, after blunting the ends, inserted into an EcoRI site of vector pcDNA/TO/GFP. To obtain pcDNA4/TO/GFP, the cDNA of green fluorescent protein (GFP) was amplified from pEGFP-C2 by PCR and was inserted into the BamHI/ApaI site of vector pcDNA4/TO. Vectors pcDNA6/TR and pcDNA4/TO were obtained from Invitrogen (Paisley, United Kingdom). pcDNA-E-cadherin-Myc and pGEX-E-cadherin were described previously (11, 17). pGEX-TEV-ß-catenin was kindly provided by B. Weise (Stanford University School of Medicine, Stanford, CA). Recombinant ß-catenin was produced by cleavage of the glutathione S-transferase (GST) tag using AcTEV protease (Invitrogen) at 4°C overnight, followed by affinity chromatography according to the manufacturer's instructions.
IC261 (CK1 inhibitor), H-89 (protein kinase A [PKA] inhibitor), glycogen synthase kinase 3ß (GSK-3ß) inhibitor II, and cycloheximide were purchased from Calbiochem (Darmstadt, Germany). A His6-tagged constitutively active form of the CK1
protein was purchased from Sigma, and protein kinase C
(PKC
) and casein kinase 2 (CK2) proteins were obtained from Calbiochem. An active form of GSK-3ß protein was obtained from Upstate. Lipofectamine Plus reagent and essential amino acids were obtained from Invitrogen. [
-32P]ATP and [32P]orthophosphate were purchased from GE Healthcare (Piscataway, NJ). Site-directed mutagenesis was performed using a QuikChange site-directed mutagenesis kit from Stratagene (La Jolla, CA).
Immunoprecipitation, GST-E-cadherin pull-down assay, and Western blotting. Immunoprecipitation was performed as described previously by using 1% Triton X-100 lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, and 1% Triton X-100) containing 5 µg ml1 leupeptin, 50 mM phenylmethylsulfonyl fluoride, and 7.2 trypsin inhibitor units of aprotinin (17). To exclude ß-catenin from the E-cadherin immunoprecipitate, MCF-7 cells were lysed in 1% Triton X-100 lysis buffer containing 1% sodium dodecyl sulfate (SDS). The lysate was then diluted 10-fold with 1% Triton X-100 lysis buffer before immunoprecipitation.
For GST-E-cadherin pull-down assays, 10 µl of glutathione-Sepharose beads (Pharmacia) attached to 6 µg GST or GST-E-cadherin protein was incubated with cell lysates in 1% Triton X-100 lysis buffer, followed by the same procedures as described above. For GST-E-cadherin mutant pull-down assays, radioimmunoprecipitation assay buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS containing the same protease inhibitors as described above) was used. Western blotting was performed as described previously (17).
Cell culture, immunofluorescence, microinjection, RNA interference, endocytosis assay, and membrane-targeting experiment.
HEK293, MCF-7, MDCK, and L fibroblast cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 1% penicillin-streptomycin at 37°C and ambient air supplemented with 5% CO2. MDCK epithelial cells transformed with a temperature-sensitive Src mutant (ts-Src MDCK cells) were cultured as described previously (2). To obtain cells expressing E-cadherin mutants, MDCK and L fibroblast cells were transfected with the pcDNA-Myc-E-cadherin wild type or S846A or S846D mutants using Lipofectamine Plus reagent, and stably transfected cells were selected in medium containing 800 µg ml1 of G418 (Calbiochem). More than five stable clones were obtained from two independent transfections for each construct. It should be noted that the expression of E-cadherin S846D decreases in both MDCK and L fibroblast cells as the passage proceeds. Thus, cells in earlier passages were used for the experiments. Since we could not obtain MDCK cells stably expressing CK1 by a conventional method, a Tet-ON inducible system was used. First, MDCK cells were transfected with pcDNA6/TR, followed by selection in medium containing 5 µg ml1 of blasticidin (Invitrogen). pcDNA4/TO/GFP-CK1
was then used for the second transfection, and the doubly transfected cells were selected in medium containing 5 µg ml1 of blasticidin and 400 µg ml1 of zeocin (Invitrogen). Sixteen hours after the addition of tetracycline, induced expression of GFP-CK1
was examined. For the experiments indicated as being "under low-confluence conditions" or "at low density," 2 x 105 and 5 x 105 cells were plated in 6-well plates and 6-cm dishes, respectively, and after 16 h, experiments were carried out. Otherwise, 6 x 105, 1.5 x 106, and 5 x 106 cells were plated in 6-well plates and 6- and 9-cm dishes, respectively, and experiments were started after 24 to 48 h. IC261 (10 µM), H-89 (200 nM), and GSK-3ß inhibitor II (1 µM) were added for 4 h unless otherwise indicated.
Calcium was depleted from fetal calf serum, and the low-calcium medium was reconstituted as described previously (3). Immunofluorescence was performed as previously described (17). Microinjection was performed as described previously (3). pCAN-Myc-CK1
or pCAN-Myc-CK1
(0.1 µg µl1 phosphate-buffered saline [PBS]) was microinjected into the nucleus of MCF-7 cells. After microinjection, cells were incubated in normal calcium medium for 6 h, followed by immunostaining with the indicated antibodies. Cell aggregation and cell dissociation assays were performed as described previously (30, 38). In a dissociation assay for cells with IC261, cell clumps were incubated for 2 h after medium was replaced with that containing 10 µM IC261. Validated small interfering RNA oligonucleotides for CK1
or CK1
were obtained from QIAGEN. Oligonucleotides were transfected into MCF-7 cells using Hi-Perfect reagent (QIAGEN) according to the manufacturer's instructions. Maximally, 50% reduction of endogenous CK1 protein was obtained by either small interfering RNA. The endocytosis assay was performed as previously described (11), except that after biotinylation, cells were incubated at 18°C to block the recycling of internalized E-cadherin back to the plasma membrane (21), and bafilomycin was not used. To examine the targeting of newly synthesized E-cadherin into the plasma membrane, we combined pulse-chase and surface biotinylation assays. First, cells were metabolically labeled as described previously (11), except that [35S]methionine and cysteine were used for 30 min. Cells were then incubated with 0.5 mg ml1 sulfo-N-hydroxysulfosuccinimide-SS-biotin in the presence or absence of 10 µM IC261 in Krebs-Ringer buffer at 37°C for 30 min or 2 h. Surface-biotinylated E-cadherin was pulled down with 20 µl of monomeric avidin beads, followed by elution with 2 mM D-biotin in PBS and immunoprecipitation with anti-E-cadherin antibody. An Immobilized Monomeric Avidin kit (Pierce, Rockford, IL) was used for the purification of biotinylated proteins.
Immunofluorescent images were analyzed by confocal microscopy unless otherwise indicated. To quantify the images in Fig. 9d, images were captured at every 0.5-µm interval, and the image where colocalization of E-cadherin and EEA-1 was maximally observed was chosen for analysis. To obtain epifluorescence and confocal images, we used a Zeiss Axioskop 1 with a Roper Scientific Coolsnap camera and a Bio-Rad MRC 1024 mounted on a Nikon Optiphot 2 microscope, respectively. To obtain phase-contrast images, we used a Leica DMIRB microscope with a Hamamatsu C4742-95 Orca camera. Images were captured and analyzed using Openlab (Improvision) and ImageJ 1.36b (National Institutes of Health).
![]() View larger version (30K): [in a new window] |
FIG. 9. Mutations in the major CK1 phosphorylation residue of E-cadherin affect endocytosis of E-cadherin. (a) Effect of IC261 on endocytosis of endogenous E-cadherin (E-cad) in MCF-7 cells. E-cadherin in MCF-7 cells was surface biotinylated and incubated in normal (N) or low-Ca2+ (L) medium in the presence or absence of 10 µM IC261 for 5 h. Biotinylated proteins on the plasma membrane were then stripped off by glutathione treatment. Biotinylated E-cadherin inside cells was recovered on streptavidin beads and analyzed by Western blotting (WB) with anti-E-cadherin antibody (Ab). Input indicates total biotinylated E-cadherin. (b and c) Effect of E-cadherin mutation on its endocytosis in MDCK cells. (b) Wild-type and nonphosphorylatable (S846A) E-cadherin on the respective stable clones (WT28 and A28) were surface biotinylated and incubated in normal (N) or low-Ca2+ (L) medium for 8 h. After glutathione treatment, biotinylated E-cadherin inside cells was recovered on streptavidin beads and analyzed by Western blotting with anti-Myc antibody. Input indicates total biotinylated Myc-E-cadherin. (c) Wild-type E-cadherin (WT) and pseudophosphorylated E-cadherin (S846D) on the respective stable clones (WT25 and D23) were analyzed as described above, except that cells were incubated in normal (N) or low-Ca2+ (L) medium for 3 h. Input indicates total biotinylated Myc-E-cadherin. The lower panel shows the quantification of endocytosed E-cadherin compared with total biotinylated E-cadherin from the results of three independent experiments. It should be noted that different incubation times were used in b (8 h) and c (3 h) in order to maximize the difference in endocytosis between respective mutants. (d) Effect of E-cadherin mutation on its endocytosis in MDCK cells by immunofluorescence staining. Myc-tagged wild-type or pseudophosphorylated (S846D) E-cadherin was transiently expressed in MDCK cells and incubated with 2.5 µg ml1 cycloheximide for 8 h. Cycloheximide was used to block the entry of newly synthesized E-cadherin into endosomes. The subcellular localization of exogenously expressed E-cadherin and early endosomes was analyzed using anti-Myc and anti-EEA1 antibodies. Scale bar, 20 µm. Expression of E-cadherin S846D induced flattening of cells as seen in Fig. 7b, and more early endosomes were observed in the same plane as E-cadherin in confocal microscopic analyses. Neither the E-cadherin wild type nor S846D affected the morphology of early endosomes.
|
-32P]ATP and the indicated kinase at 30°C for 8 min while shaking at 1,400 rpm, followed by washing with ice-cold phosphorylation buffer three times, boiling in SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer, and SDS-PAGE. For CK1, to optimize phosphorylation conditions, the time-dependent and kinase dose-dependent reactions were first studied, and we used an 8-min reaction time and 0.2 µg CK1
protein for all the experiments except for maximal phosphorylation. To examine maximal phosphorylation of E-cadherin by CK1
, the phosphorylation reaction was performed with 1.2 µg CK1
for 30 min. A total of 0.2 µg PKC
, 0.2 µg GSK-3ß, or 250 U of CK2 was also used for a phosphorylation assay. In vivo phosphorylation assay. Krebs-Ringer buffer (20 mM HEPES-NaOH [pH 7.4], 118 mM NaCl, 4.75 mM KCl, 1.2 mM MgCl2, 0.26 mM CaCl2, 25 mM NaHCO3, 0.45% glucose, and 1x essential amino acids) was used for the phosphorylation assay. For low-Ca2+ treatment, CaCl2 was excluded from the buffer. MCF-7 cells in a 6-cm dish were first preincubated in Krebs-Ringer buffer for 1 h and further incubated in 1 ml of Krebs-Ringer buffer containing 0.5 mCi [32P]orthophosphate in the presence or absence of IC261 for 2 h, when [32P]orthophosphate was converted into [32P]ATP inside cells followed by the phosphorylation of proteins. IC261 did not grossly affect the radioactivity of total cell lysates, suggesting that it did not block the conversion from orthophosphate to ATP. Cells were then washed twice with PBS and precleared by mouse control immunoglobulin G beads prior to immunoprecipitation with anti-E-cadherin antibody.
Statistical analysis.
Descriptive statistics on the dissociation indices (DI) were calculated with NCSS software. Student's t tests were then generated with a threshold equal to 5% (
= 0.05). The DI data were transformed to arcsin (square DI), and Student's t tests were achieved with NCSS software using these values because this test requires variables with no fixed limits.
|
|
|---|
1 µM for CK1
and CK1
and a 50% inhibitory concentration of
10 µM for CK1
(26). The cell-cell contact stabilization effect was seen in the presence of 2.5 µM IC261 (data not shown); however, the maximal effect was observed with 10 µM IC261, suggesting that the inhibition of not only CK1
and CK1
but also other isoforms including CK1
is attributed to the effect of IC261.
![]() View larger version (55K): [in a new window] |
FIG. 1. CK1 inhibitor IC261 stabilizes N-cadherin-based cell-cell contacts in HEK293 cells. (a) Effect of various kinase inhibitors on HEK293 cells. HEK293 cells were incubated with 1 µM GSK-3ß inhibitor II, 200 nM H-89 (PKA inhibitor), or 10 µM IC261 (CK1 inhibitor) for 4 h. The effect was examined by phase-contrast microscopy. Scale bar, 20 µm. (b) Effect of IC261 on the localization of N-cadherin in HEK293 cells. HEK293 cells were incubated in the presence (+) or absence () of 10 µM IC261 for 4 h, and the localization of N-cadherin was examined by immunofluorescence with anti-N-cadherin antibody using epifluorescence microscopy. Scale bar, 20 µm. (c) Effect of IC261 on the expression of the N-cadherin complex. HEK293 cells were incubated in the presence or absence of 10 µM IC261 for 4 h, followed by immunoprecipitation (IP) with anti-N-cadherin antibody and Western blotting (WB) with anti-N-cadherin and anti-ß-catenin antibodies.
|
![]() View larger version (74K): [in a new window] |
FIG. 2. CK1 inhibitor IC261 stabilizes E-cadherin-based cell-cell contacts in MCF-7 and L fibroblast cells. (a) Effect of IC261 on MCF-7 cells under low-confluence conditions. MCF-7 cells cultured at low density were incubated in the presence or absence of 10 µM IC261 for 4 h. The effect of IC261 was examined by phase-contrast and immunofluorescence (IF) microscopy with anti-E-cadherin antibody (Ab). Scale bars, 20 µm. (b and c) Effect of IC261 on low-Ca2+-induced cell separation in MCF-7 cells. MCF-7 cells were incubated in low-Ca2+ medium in the presence or absence of 10 µM IC261 for the indicated times. The effect of the treatment was examined by phase-contrast microscopy (b) and immunofluorescence microscopy with anti-ß-catenin antibody (c). Scale bars, 20 µm. (d) Requirement of E-cadherin for the effect of IC261 on cell-cell contacts. L cells or L cells expressing E-cadherin were incubated in the presence or absence of 10 µM IC261 for 4 h. The effect of IC261 was examined by phase-contrast microscopy. Scale bar, 20 µm.
|
![]() View larger version (34K): [in a new window] |
FIG. 5. CK1 phosphorylates the cytoplasmic domain of E-cadherin. (a and b) Effect of IC261 on phosphorylation of the E-cadherin complex in MCF-7 cells in an in vivo phosphorylation assay. MCF-7 cells were cultured at low (a) or high (b) density and incubated with [32P]orthophosphate in the presence or absence of 10 µM IC261 for 2 h. In b, cells were incubated in either normal (N) or low-Ca2+ (L) medium. Cell lysates were immunoprecipitated with anti-E-cadherin antibody, followed by SDS-PAGE, autoradiography, and Western blotting (WB) with the indicated antibodies (Ab). The proteins in the autoradiography bands were identified by comparing them with the accompanying Western blotting results. (c) Phosphorylation of the cytoplasmic domain of E-cadherin by an in vitro phosphorylation assay. GST or the GST-tagged cytoplasmic domain of E-cadherin was incubated with [ -32P]ATP in the presence of CK1 or PKC . Phosphorylated proteins were subjected to SDS-PAGE, followed by autoradiography and Coomassie protein staining. (d) Amino acid sequence alignment of the cytoplasmic domains of classical cadherins. The sequence of E-, N-, OB-, VE-, and P-cadherins are from a mouse protein database. C- and DE-cadherins are E-cadherin counterparts from frog and fly, respectively. The numbers indicate the amino acid numbers for mouse E-cadherin. The potential major CK1 phosphorylation site of cadherins is in red. An analogous CK1 phosphorylation site of ß-catenin is also shown. (e) Determination of the major CK1 phosphorylation site of E-cadherin by an in vitro phosphorylation assay. The GST-tagged wild type (WT) and nonphosphorylatable E-cadherin mutants were incubated with [ -32P]ATP in the presence of CK1 or CK2, followed by autoradiography and Coomassie protein staining. ASSS, S846A; SAAA, S849A, S852A, and S855A; AAAA, S846A, S849A, S852A, and S855A.
|
100 µM), the extracellular domains of E-cadherin form only weak and transient homophilic interactions, and cells dissociate from one another (Fig. 2b, upper panels). Interestingly, when IC261 was added to the low-Ca2+ medium, the dissociation process was prevented. The cells remained attached to each other (Fig. 2b, lower panels), and ß-catenin was still localized at cell-cell contacts (Fig. 2c), suggesting that E-cadherin-based intercellular adhesions are maintained. To quantify the effect of IC261, we incubated cells in suspension in low-Ca2+ medium with or without 10 µM IC261 for 2 h, and cell aggregates were counted after trypsin treatment in the presence of Ca2+ (TC treatment) or EGTA (TE treatment) (30). The cell DI (NTC/NTE, where NTC and NTE are the total particle numbers after the TC and TE treatment) were 0.34 and 0.14 in the cells cultured in the absence and presence of IC261, respectively, and the difference was statistically significant (P < 0.005). To further examine this effect, IC261 was added to cells following dissociation in low-Ca2+ medium. After 2 to 3 h of IC261 incubation, the cells re-formed cell-cell contacts even in low-Ca2+ medium (see Fig. S1a in the supplemental material). Thus, IC261 not only blocks cell separation but also reverts cell-cell contact formation under low-Ca2+ conditions. To investigate whether the effect of IC261 depends on cadherin, we used L fibroblast cells that do not express endogenous classical cadherins and thus do not form stable cell-cell contacts. The addition of IC261 to L cells did not induce the formation of cell-cell contacts, and some cells rounded up, probably due to effects on the cytoskeleton (Fig. 2d, upper panels). In contrast, L cells stably expressing E-cadherin formed weak and immature cell-cell adhesions when plated at low densities (Fig. 2d, lower left panels). Upon the addition of IC261, they tightly adhered to each other and formed compact cell-cell contacts (Fig. 2d, lower right panel), indicating that IC261 requires E-cadherin to promote cell-cell contact formation.
To examine whether IC261 affects the disruption of E-cadherin-based cell-cell contacts induced by Src, we used ts-Src MDCK cells. At 40.5°C (the nonpermissive temperature for ts-Src activity), cells formed tight intercellular adhesions. In contrast, when shifted to 35°C (the permissive temperature for ts-Src activity), cells dissociated from one another and acquired a spindle-like morphology (see Fig. S1b, upper panels, in the supplemental material) (2, 11). This shape change was accompanied by a redistribution of E-cadherin from the plasma membrane to intracellular compartments (see Fig. S1b, lower panels, in the supplemental material). The addition of IC261 did not significantly affect either this morphological change or the E-cadherin relocalization at 35°C (see Fig. S1b in the supplemental material). Thus, IC261 does not affect tyrosine kinase- and ubiquitin-dependent disruption of cell-cell contacts.
We also investigated the effect of the overexpression of CK1 on E-cadherin-based cell-cell contacts by microinjecting the cDNA encoding CK1
into the nucleus of MCF-7 epithelial cells. Between microinjected cells, the level of E-cadherin and ß-catenin at cell-cell contacts was significantly reduced, compared with that between nonmicroinjected cells (Fig. 3). The microinjection of the cDNA encoding CK1
also induced a similar effect but to a lesser extent (data not shown), which may be due to its autoinhibitory domain. Microinjection of the empty vector had no effect (data not shown). These data suggest that CK1 has an inhibitory role in the formation of E-cadherin-based cell-cell contacts, consistent with the observation that IC261 stabilizes them.
![]() View larger version (52K): [in a new window] |
FIG. 3. Overexpression of CK1 disrupts E-cadherin-based cell-cell contacts. The cDNA of Myc-tagged CK1 was microinjected into the nucleus of MCF-7 cells. The effect of expression of CK1 on E-cadherin-based cell-cell contacts was analyzed by immunofluorescence microscopy with the indicated antibodies. Scale bar, 40 µm.
|
in MDCK cells by immunostaining with anti-CK1
antibody. At steady state, CK1
accumulated at cell-cell contact sites, where it colocalized with E-cadherin (Fig. 4a). We further examined whether CK1 localization is dynamically regulated under Ca2+ switch conditions. In low-Ca2+ medium, MDCK cells lost their tight E-cadherin-based cell-cell contacts, and CK1
was diffusely distributed into the cytosol and was no longer concentrated at the plasma membrane (Fig. 4b, upper panels). Upon reversion to normal Ca2+ medium, E-cadherin accumulated at cell-cell adhesion sites. CK1
was recruited to these newly forming cell-cell contact sites, although the time course of this recruitment was slightly slower than that of E-cadherin (Fig. 4b, middle and lower panels). By using MDCK cells stably expressing GFP-tagged CK1
, we observed a similar subcellular localization of CK1
(see Fig. S2 in the supplemental material). Thus, CK1
colocalizes with E-cadherin at cell-cell contact sites, and this localization is dynamically regulated during the formation of cell-cell adhesions.
![]() View larger version (35K): [in a new window] |
FIG. 4. CK1 colocalizes and interacts with E-cadherin. (a and b) Colocalization between CK1 and E-cadherin in MDCK cells at steady state (a) or during Ca2+ switch (b). The subcellular localization of E-cadherin and CK1 was examined in MDCK cells using anti-E-cadherin and anti-CK1 antibodies. Scale bars, 10 µm. (c) Interaction between CK1 and E-cadherin (E-cad) by GST pull-down assays. Beads coupled to GST or the GST-tagged E-cadherin cytoplasmic domain were incubated with MCF-7 cell lysates. The proteins bound to the beads were analyzed by Coomassie protein staining and Western blotting (WB) with anti-CK1 and anti-CK1 antibodies (Ab). The arrow and arrowhead indicate the positions of GST-E-cadherin and GST, respectively.
|
from MCF-7 cells bound to GST-E-cadherin-coupled beads but not to GST-coupled beads (Fig. 4c, upper panel). Endogenous CK1
also showed a strong preference for GST-E-cadherin beads (Fig. 4c, middle panel). The interaction was further examined by immunoprecipitation using MCF-7 or MDCK cells. However, we could not consistently detect coimmunoprecipitation between E-cadherin and CK1 (data not shown), suggesting that the interaction occurs transiently or catalytically in cells.
CK1 phosphorylates the cytoplasmic domain of E-cadherin.
We used an in vivo phosphorylation assay to examine whether CK1 phosphorylates the components of the E-cadherin complex. MCF-7 cells were incubated with 32P-labeled orthophosphate in the presence or absence of IC261, followed by immunoprecipitation with anti-E-cadherin antibody, SDS-PAGE, and autoradiography. In the E-cadherin complex, phosphorylation of E-cadherin,
-catenin, and ß-catenin was detected (Fig. 5a and b). Under low-confluence conditions, the addition of IC261 reduced the phosphorylation of E-cadherin and
-catenin by approximately 50% (Fig. 5a). Both proteins remained phosphorylated even in the presence of IC261, suggesting that kinases other than CK1 also phosphorylate E-cadherin and
-catenin. When cells were cultured at higher densities, the phosphorylation of E-cadherin was not affected by IC261 (Fig. 5b); thus, the confluence of cells affects the phosphorylation of E-cadherin. However, when cells were incubated in low-Ca2+ medium, IC261 suppressed the phosphorylation of E-cadherin (Fig. 5b). IC261 reduced the phosphorylation of
-catenin under both normal and low-Ca2+ conditions but had no effect on the phosphorylation of ß-catenin. The amounts of ß-catenin and
-catenin bound to E-cadherin were not affected under these experimental conditions (Fig. 5a and b and data not shown). These data indicate that CK1 phosphorylates both E-cadherin and
-catenin in MCF-7 cells.
It has been reported that CK1 phosphorylates serine 45 of ß-catenin, which primes the subsequent phosphorylation by GSK-3ß and enhances the proteasomal degradation of ß-catenin (23, 40). We produced nonphosphorylatable (S45A) and pseudophosphorylated (S45D) ß-catenin mutants and studied whether such mutations affect the adhesive properties of ß-catenin in epithelial cells. However, both mutants localized at cell-cell contact sites in MDCK cells and bound equally to E-cadherin in a GST-E-cadherin pull-down assay (data not shown). Thus, we could not obtain any data indicating a significant role of CK1-mediated phosphorylation of ß-catenin in the formation of cell-cell contacts. Therefore, we focused on the CK1-mediated phosphorylation of E-cadherin. The significance of CK1-mediated phosphorylation of
-catenin is currently being investigated.
Next, we studied whether CK1 can directly phosphorylate E-cadherin. Using an in vitro phosphorylation assay, we found that purified CK1
protein efficiently phosphorylates GST-E-cadherin but not GST (Fig. 5c). By contrast, another kinase, PKC
, did not phosphorylate GST-E-cadherin, suggesting that CK1 specifically phosphorylates E-cadherin. About 0.8 mol of phosphate was maximally incorporated into 1 mol of E-cadherin (data not shown), indicating that E-cadherin is indeed a prominent substrate of CK1.
There are three known substrate consensus sequences for CK1 phosphorylation: D/EXXS/T, PO4-S/TXXS/T, and SLS (where X is any amino acid and S/T in boldface indicates the phosphorylation site). In the case of ß-catenin, S45 matches with the third consensus sequence, SLS (Fig. 5d). To determine the CK1 phosphorylation sites of E-cadherin, we first aligned the amino acid sequences of the cytoplasmic domains of several classical cadherins from different species. Interestingly, in the ß-catenin-binding site, there is a highly conserved region that includes SLS at amino acid position 846 in murine E-cadherin (Fig. 5d). There are other conserved serine/threonine residues at amino acid positions 849, 852, and 855 in murine E-cadherin. They satisfy the second consensus sequence, PO4-S/TXXS/T, that could be sequentially phosphorylated following the primed S846 phosphorylation. To identify the CK1 phosphorylation sites on E-cadherin, we tested a series of nonphosphorylatable mutants of E-cadherin (at amino acids 846, 849, 852, and/or 855) for phosphorylation in vitro. The single-amino-acid substitution S846A reduced CK1-catalyzed phosphorylation by 70 to 80%, while mutations at positions 849, 852, and 855 did not affect the level of phosphorylation (Fig. 5e, left panels). This indicates that S846 is the major phosphorylation site for CK1. We also tested mutations of other residues (T750 and S848), but phosphorylation was not affected by these mutations (data not shown). Thus, other minor CK1 phosphorylation sites on E-cadherin remain to be clarified. CK2 is another serine/threonine kinase that has been reported to phosphorylate E-cadherin and enhance E-cadherin-ß-catenin interactions (22). For CK2, the mutation at position 846 did not affect phosphorylation; instead, the mutations at positions 849, 852, and 855 reduced phosphorylation (Fig. 5e, right panels). These data indicate that CK1 and CK2 phosphorylate distinct serine residues.
It was shown previously that CK1-catalyzed phosphorylation primes the subsequent phosphorylation of ß-catenin by GSK-3ß (23). E-cadherin also contains a serine residue at S842, although not conserved in fly, which matches with a substrate consensus sequence for GSK-3ß phosphorylation (S/TXXXS-PO4) following the CK1-catalyzed phosphorylation at S846 (Fig. 5d). However, CK1-catalyzed phosphorylation of E-cadherin did not prime the phosphorylation by GSK-3ß in in vitro phosphorylation assays (see Fig. S3 in the supplemental material), and GSK-3ß inhibitor did not affect the effect of IC261 on cell dissociation (data not shown).
CK1-induced phosphorylation of E-cadherin attenuates its adhesive function at cell-cell contact sites. To explore the functional significance of the CK1-induced phosphorylation of E-cadherin, we mutated the major phosphorylation residue S846 into alanine (S846A) and aspartic acid (S846D) to produce nonphosphorylatable and pseudophosphorylated mutant forms of E-cadherin, respectively. The Myc-tagged wild-type and mutant forms of E-cadherin were stably expressed in L fibroblast cells, and more than five independent clones were analyzed for each of the different forms of E-cadherin. Upon expression of wild-type or nonphosphorylatable E-cadherin, L cells formed stable cell-cell contacts under high-confluence conditions and became epithelium-like (Fig. 6b, left and middle panels). In contrast, L cells expressing the pseudophosphorylated E-cadherin mutant did not form tight cell-cell contacts and remained fibroblastic (Fig. 6b, right panel), despite a similar level of E-cadherin expression (Fig. 6a). Consistently, when cultured in suspension, L cells expressing wild-type or nonphosphorylatable E-cadherin formed large cell aggregates, while those expressing the pseudophosphorylated E-cadherin did not (Fig. 6c). Differences in the strengths of cell-cell adhesions were quantified using TC treatment or TE treatment (30). Cell aggregates were counted, and the cell DI (NTC/NTE, where NTC and NTE are the total particle numbers after the TC and TE treatment) was calculated (Table 1). This index was 0.64, 0.46, and 0.88 in the cells expressing wild type, S846A, and S846D E-cadherin, respectively. The differences between the wild type and S846A and between the wild type and S846D are statistically significant (P < 0.01 and P < 0.005, respectively). Furthermore, we examined the effect of the mutations on the localization of E-cadherin by immunofluorescence. Both wild-type and nonphosphorylatable E-cadherin accumulated at cell-cell contact sites, while pseudophosphorylated E-cadherin was diffusely distributed in the cytosol and on the plasma membrane (Fig. 6d). Taken together, these data indicate that the single-amino-acid substitution in the major CK1 phosphorylation site of E-cadherin influences the adhesive activity of E-cadherin and that upon phosphorylation on S846, E-cadherin is unable to localize at cell-cell contact sites or to mediate stable intercellular adhesions.
![]() View larger version (77K): [in a new window] |
FIG. 6. Mutations in the major CK1 phosphorylation residue of E-cadherin affect adhesiveness of cell-cell contacts in L fibroblast cells stably expressing E-cadherin mutants. L fibroblast clones stably expressing the Myc-tagged wild type and nonphosphorylatable (S846A) and pseudophosphorylated (S846D) mutants of E-cadherin were obtained. More than five independent clones were analyzed for each of the different types of E-cadherin, and analogous data were obtained between clones expressing the same type of E-cadherin. The data using representative clones (WT2, A5, and D13 for wild-type, S846A, and S846D E-cadherin, respectively) are shown. (a) Expression level of E-cadherin mutants in the L fibroblast clones. Cell lysates (20 µg of proteins) from the indicated clones were analyzed by Western blotting (WB) with anti-Myc antibody (Ab). (b) Effect of mutations of E-cadherin on cell-cell contact formation. Nontransfected cells or the indicated clones were cultured at high density and analyzed by phase-contrast microscopy. Scale bar, 40 µm. (c) Effect of mutations of E-cadherin on formation of cell aggregates. Nontransfected cells or the indicated clones were cultured in suspension and examined by phase-contrast microscopy. Scale bar, 40 µm. (d) Effect of mutations on subcellular localization of E-cadherin. The indicated clones were cultured at low density and analyzed by immunostaining with anti-Myc antibody. Scale bar, 20 µm. IF, immunofluorescence. (e) Effect of mutations of E-cadherin on IC261-induced stabilization of cell-cell contacts. The indicated clones were cultured at a low density in the presence or absence of 10 µM IC261 for 4 h and analyzed by phase-contrast microscopy. Scale bar, 20 µm.
|
|
View this table: [in a new window] |
TABLE 1. Cell DI of L cells expressing E-cadherin mutants in the presence or absence of IC261a
|
To investigate the significance of CK1-mediated phosphorylation of E-cadherin further, we established MDCK epithelial cells stably expressing the E-cadherin mutants (Fig. 7A). The expression of wild-type or S846A E-cadherin did not induce obvious morphological changes, and both exogenous and endogenous E-cadherin accumulated at cell-cell contact sites (Fig. 7b, left and middle panels). In contrast, cells expressing S846D E-cadherin were more flattened, with some fibroblastic characteristics also observed, and both exogenous S846D and endogenous E-cadherin failed to accumulate at cell-cell adhesions (Fig. 7b, right panel). As the cell density increased, however, both endogenous and exogenous S846D E-cadherin accumulated at cell-cell contact sites (data not shown). Thus, in epithelial cells, the expression of pseudophosphorylated E-cadherin induced a dominant-negative effect, inhibiting the formation of cell-cell contacts under conditions of low confluence.
![]() View larger version (59K): [in a new window] |
FIG. 7. Mutations in the major CK1 phosphorylation site of E-cadherin affect localization of E-cadherin in MDCK cells stably expressing E-cadherin mutants. MDCK cell clones stably expressing the Myc-tagged wild type and nonphosphorylatable (S846A) and pseudophosphorylated (S846D) mutants of E-cadherin were obtained. More than five independent clones were analyzed for each of the different types of E-cadherin, and analogous data were obtained between clones expressing the same types of E-cadherin. Data using representative clones (WT25 and WT28, A28, and D23 for wild-type, S846A, and S846D E-cadherin, respectively) are shown. (a) Expression level of E-cadherin mutants in MDCK cell clones. Cell lysates (20 µg of proteins) from the indicated clones were analyzed by Western blotting (WB) with anti-Myc and anti-E-cadherin antibodies (Ab). The arrowhead and arrow indicate the positions of exogenous Myc-tagged E-cadherin and endogenous E-cadherin, respectively. (b) Effect of mutations in the major CK1 phosphorylation site of E-cadherin on its localization in MDCK cells. The indicated clones were examined by phase-contrast microscopy and immunofluorescence (IF) microscopy with anti-Myc and anti-E-cadherin antibodies. It should be noted that anti-E-cadherin antibody detects both exogenous and endogenous E-cadherin. Scale bars, 20 µm.
|
at 30°C and then mixed with HEK293 cell lysates, followed by GST pull-down assays. The amounts of E-cadherin-bound ß-catenin or p120 catenin from the lysates were examined by Western blotting. CK1
bound both the E-cadherin wild type and S846A and enhanced the interaction of E-cadherin with ß-catenin but not with p120 (Fig. 8a, upper panels). This effect of CK1
was observed even when CK1
and E-cadherin were incubated with ATP
S (see Fig. S4a in the supplemental material). Taken together with the data showing that CK1
can directly interact with ß-catenin (Fig. 8a, lower panels), the effect of CK1
on the increased binding between E-cadherin and ß-catenin is not through phosphorylation but is through the formation of a ternary complex between three proteins. Interestingly, in the presence of CK1
, a higher amount of ß-catenin bound to E-cadherin S846A than to the E-cadherin wild type (Fig. 8a, upper panel). Next, we tested whether CK1 phosphorylation of E-cadherin itself affects the affinity of E-cadherin for its binding proteins. Beads coupled to GST-E-cadherin S846A or S846D were incubated with HEK293 cell lysates. When titration was performed with decreasing amounts of cell lysates, it was revealed that the interaction of ß-catenin with pseudophosphorylated E-cadherin was weaker than that with nonphosphorylatable E-cadherin (Fig. 8b, upper panel). Interactions with p120 were not suppressed by the mutations (Fig. 8b, middle panel). These results indicate that E-cadherin, ß-catenin, and CK1
can form a ternary protein complex but that once E-cadherin is phosphorylated, direct interactions between E-cadherin and ß-catenin are reduced.
![]() View larger version (58K): [in a new window] |
FIG. 8. CK1-catalyzed phosphorylation of E-cadherin affects the interaction between E-cadherin and ß-catenin and vice versa. (a) Effect of CK1 on the interaction between E-cadherin and the binding proteins. (Upper panel) GST or the GST-tagged cytoplasmic domain of wild-type (WT) or nonphosphorylatable (S846A) E-cadherin was coupled to glutathione-Sepharose beads and incubated with ATP in the presence or absence of His6-tagged CK1 at 30°C for 30 min. The beads were then incubated with HEK293 cell lysate at 4°C, followed by GST pull-down assays. The proteins bound to the beads were analyzed by Coomassie protein staining and Western blotting (WB) with anti-His6 antibody (Ab). (Lower panel) GST or GST-ß-catenin was coupled to glutathione-Sepharose beads and incubated with His6-CK1 , followed by GST pull-down assays. The proteins bound to the beads were analyzed by Coomassie protein staining and Western blotting with the indicated antibodies. (b) Effect of mutations of E-cadherin on its interaction with binding proteins. GST or the GST-tagged cytoplasmic domain of nonphosphorylatable (S846A) or pseudophosphorylated (S846D) E-cadherin was coupled to glutathione-Sepharose beads. The beads were then incubated with the titrated amount of HEK293 cell lysate (one-half, one-quarter, or one-eighth of cell lysate from an 80% confluent culture in a 9-cm plate). The proteins bound to the beads were analyzed by Coomassie protein staining and Western blotting with the indicated antibodies. (c) Interaction between E-cadherin and ß-catenin prevents phosphorylation of E-cadherin by CK1. To uncouple ß-catenin from E-cadherin, MCF-7 cells were lysed in 1% SDS lysis buffer. The lysate was then diluted 10-fold prior to immunoprecipitation (IP). Otherwise, immunoprecipitation was performed in 1% Triton X-100 lysis buffer. After immunoprecipitation, beads were intensively washed, and in vitro phosphorylation assays were performed with [ -32P]ATP and CK1 , followed by autoradiography and Western blotting with anti-E-cadherin, - -catenin, and -ß-catenin antibodies. Arrows indicate the positions of E-cadherin, -catenin, and ß-catenin.
|
-catenin and ß-catenin that bound to E-cadherin were phosphorylated by CK1 (Fig. 8c). Taken together, these data suggest that dissociation from ß-catenin promotes the phosphorylation of E-cadherin by CK1. We then examined whether CK1 is involved in the endocytosis of E-cadherin by using surface biotinylation assays. Under low-Ca2+ conditions, the endocytosis of E-cadherin is enhanced, leading to a disruption of E-cadherin-based cell-cell contacts (21). In the presence of IC261, this low-Ca2+-induced separation of cell-cell adhesions is strongly suppressed in MCF-7 cells (Fig. 2b and c). Indeed, the biotinylation assay revealed that the internalization of E-cadherin induced by low-Ca2+ treatment was suppressed by IC261 (Fig. 9a). We also examined whether CK1 phosphorylation of E-cadherin affects the endocytosis of E-cadherin in MDCK cells. Upon low-Ca2+ treatment, nonphosphorylatable E-cadherin (S846A) was not efficiently endocytosed compared with wild-type E-cadherin (Fig. 9b). In contrast, pseudophosphorylated E-cadherin (S846D) was more efficiently internalized from the plasma membrane than wild-type E-cadherin (Fig. 9c). The endocytosis of E-cadherin S846D was not significantly suppressed by IC261 (see Fig. S4c in the supplemental material). The internalization of the E-cadherin wild type and that of S846D were further compared by using immunofluorescent analysis. As shown in Fig. 9d, higher amounts of E-cadherin S846D were localized in early endosomes than those of the E-cadherin wild type. The quantification of the immunostaining intensity showed that the percentages of endosomal E-cadherin relative to overall E-cadherin were 5.7% and 13.3% for the E-cadherin wild type and S846D, respectively (statistically different; P < 0.01 [n = 10]). These data indicate that CK1 plays a positive role in the endocytosis of E-cadherin and that E-cadherin is an important substrate of CK1 in this process.
Since the association of E-cadherin with ß-catenin has been reported to affect cadherin targeting to the plasma membrane (7), we also examined the involvement of CK1-catalyzed phosphorylation in this process by combining pulse-chase and surface biotinylation assays. Newly synthesized E-cadherin was metabolically labeled with 35S, and its transport to the plasma membrane was monitored by biotinylation with NHS-SS-biotin in the presence or absence of IC261 for 45 min (data not shown) or 2 h (see Fig. S4d in the supplemental material). We found that the addition of IC261 did not significantly influence the transport of newly synthesized E-cadherin to the plasma membrane, suggesting that CK1 is not involved in cadherin membrane targeting.
|
|
|---|
-factor pheromone receptor and uracil permease (16, 24, 25). CK1-induced phosphorylation of these membrane proteins primes the subsequent ubiquitination, leading to their internalization and/or sorting to the vacuole for protein degradation. In mammals, however, the mode of regulation of endocytosis by CK1 may be different. Our findings did not suggest the involvement of ubiquitination in the CK1-induced endocytosis of E-cadherin. Firstly, IC261 did not affect E-cadherin endocytosis or disruption of E-cadherin-based cell-cell contacts induced by Src, a process that is dependent on the ubiquitination of the E-cadherin complex (11). In addition, we did not detect the ubiquitination of the pseudophosphorylated (S846D) E-cadherin (data not shown).
The function of CK1 is regulated by both its subcellular localization and catalytic activity (for a review, see reference 20). In epithelial cells, we found that CK1
is localized at cell-cell contact sites, and its localization is dynamically regulated during the modulation of cell-cell contacts. When cells separate from each other, CK1
does not accumulate on the plasma membrane. However, as cells reform intercellular adhesions, CK1
is recruited at cell-cell contact sites. The molecular mechanism for this recruitment remains to be resolved. In addition, several molecular mechanisms regulate the catalytic activity of CK1. First, the C-terminal domain of CK1 contains inhibitory autophosphorylation sites. The truncation of the C terminus or the dephosphorylation of autophosphorylation sites by phosphatases increases CK1 activity (5, 6, 13). Second, in some cell types, an increase of the plasma membrane concentration of phosphatidylinositol 4,5-biphosphate reduces CK1
activity (4, 14). It is not clearly understood what physiological stimuli regulate CK1 activity in epithelial cells. One possible stimulus is the Wnt signaling pathway. Activation by Wnt-3a has been reported to activate CK1
in HEK293 cells (37). Moreover, CK1 phosphorylates various components of the Wnt signaling pathway, regulating this pathway either positively or negatively (10, 12, 23, 40, 41). Taken together with our finding that CK1-mediated phosphorylation of E-cadherin attenuates its interaction with ß-catenin, CK1 may regulate both Wnt signaling and cell-cell contacts simultaneously in epithelial cells.
There are seven isoforms (
, ß,
1,
2,
3,
, and
) of CK1 that have distinct substrate specificities and subcellular localizations (for a review, see reference 20). Whether these isoforms have distinct functions or compensate for each other seems signaling pathway and cell context dependent. For example, in a canonical Wnt signaling pathway, CK1
is a negative regulator (23), whereas CK1
3, CK1
, and CK1
positively regulate the pathway (10, 12, 27, 33, 35). In contrast, in a noncanonical Wnt pathway, CK1
cooperates with CK1
positively in planar cell polarity signaling (36). We show here that the overexpression of either CK1
or CK1
destabilizes E-cadherin-based cell-cell contacts. RNA interference of CK1
and/or CK1
in MCF-7 cells, inducing maximally a 50% reduction of endogenous CK1 proteins, did not induce any significant effects on cell morphology (data not shown). Thus, it is possible that multiple CK1 isoforms may be involved in the regulation of cell-cell contacts, depending on the cell type, which needs to be studied in the future. To further characterize the functional role of CK1 in vivo, it may be advantageous to study lower organisms that contain fewer CK1 isoforms.
Within the CH3 domain of cadherins, there are serine/threonine clusters that overlap largely with the ß-catenin-binding site. The finding that IC261 did not completely abolish E-cadherin phosphorylation suggests that another kinase(s) also phosphorylates E-cadherin. Indeed, CK2 has been shown to phosphorylate serine/threonine residues in the CH3 domain, which enhances the interaction of E-cadherin with ß-catenin (18, 22). However, the suggested CK2 phosphorylation sites (S840, S853, and S855) are not well conserved among classical cadherins of different species. In contrast, we found that S846 shows striking conservation within classical cadherins and that it is the major CK1 phosphorylation site of E-cadherin. In addition, the phosphorylation at S846 decreases the interaction with ß-catenin. Thus, the balance of CK1- and CK2-catalyzed phosphorylation may determine the binding affinity between E-cadherin and ß-catenin. Furthermore, the effect of IC261 on the stabilization of cell-cell contacts cannot be attributed solely to the S846 phosphorylation of E-cadherin (Fig. 6e), suggesting the existence of other substrate proteins for CK1. Indeed, CK1 has been reported to phosphorylate other cell-cell adhesion proteins such as occludin and connexin, although the functional significance of these phosphorylations remains to be clarified (9, 28). It is plausible that CK1 phosphorylates multiple junctional proteins in order to dynamically regulate the different types of cell-cell junctions in a coordinated manner.
Cadherin-based cell-cell adhesions are dynamically regulated during cancer metastasis, mitosis, and epithelial-mesenchymal transitions in embryonic development. It is now important to determine whether CK1-mediated phosphorylation of cadherin is involved in these processes. To resolve this, efficient experimental assays to monitor the activity of CK1 and specific antibodies against phosphorylated cadherin need to be established. Other important questions are what stimuli activate CK1 in vivo and how CK1-mediated phosphorylation of E-cadherin enhances the endocytosis of E-cadherin. Future investigations into these questions will lead us to further understand this vital molecular mechanism that dynamically regulates cell-cell adhesions.
S.D.-C. was supported by an FEBS Long Term Fellowship. A.F. was supported by a postdoctoral fellowship from Ministerio de Educacion, Cultura y Deporte of Spain. This work is supported by MRC funding to the Cell Biology Unit.
Published ahead of print on 12 March 2007. ![]()
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
Present address: INSERM UMR 757, Université Paris-Sud, Bat 443, 91405 Orsay Cedex, France. ![]()
S.D.-C. and A.F. contributed equally to this work. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»